The prognostic role of the epidermal growth factor receptor (EGFR) in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 22033-22033 ◽  
Author(s):  
C. Pauligk ◽  
R. M. Wirtz ◽  
K. Steinmetz ◽  
S. Probst ◽  
J. T. Hartmann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Factor Receptor ◽  
Metastatic Gastric Cancer ◽  
Phase Iii ◽  
Prognostic Role ◽  
First Line ◽  
Phase Iii Trial ◽  
Epidermal Growth ◽  
Line Chemotherapy

Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4509-LBA4509 ◽  
Author(s):  
E. Van Cutsem ◽  
Y. Kang ◽  
H. Chung ◽  
A. Sawaki ◽  
F. Lordick ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
First Line ◽  
Standard Chemotherapy ◽  
Her2 Positive ◽  
Phase Iii Study ◽  
Epidermal Growth ◽  
Final Text

LBA4509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document